Delivery Order SPE2DB24D2217-SPE2DB25FJWUJ
- Not listed
- The Defense Logistics Agency awarded a competitively competed delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Ingrezza 40 mg capsules (30-count packages) valued at $11,622.18, with completion required by December 1, 2025. This firm fixed price delivery order represents a non-set-aside award and will be fulfilled from the vendor's corporate office located in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's existing Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order on November 6, 2025, for $4,027.69 to supply Ingrezza 80 mg capsules (30-count units). This is a firm fixed-price contract with a completion date of December 1, 2025, and no set-aside designation was used. The award will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Ingrezza 40 mg capsules (30-count units) valued at $3,676.12. This is a firm fixed-price delivery order with an ultimate completion date of October 20, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under a larger Indefinite...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Ingrezza 60 mg capsules (30-count package) valued at $8,099.22 with a firm fixed price structure. The delivery order, which represents a non-competitive set-aside award, is scheduled for completion by October 14, 2025, and will be fulfilled from the contractor's operations in Conshohocken, Pennsylvania. This contract represents a child ordering...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ingrezza 80 mg capsules in a 30-count package, valued at $8,055.38. This competitively awarded, non-set-aside contract represents a firm fixed-price delivery order with an ultimate completion date of November 18, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's primary location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $4,027.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Ingrezza 80 mg capsules (30-count units). This is a non-set-aside, competitively awarded contract with an ultimate completion date of May 15, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 9, 2025, for the supply of Ingrezza 80 mg capsules (30-count units) with a ceiling value of $4,027.70 and a firm fixed price structure. This order is set to be completed by July 30, 2025, and represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location, leveraging its...
- The Defense Logistics Agency awarded a $4,049.61 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Ingrezza 60 mg capsules (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ingrezza 40 mg capsules (quantity: 30 units) with a ceiling value of $14,704.48. This is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,676.12 to AmerisourceBergen Drug Corp for the supply of Ingrezza 40 mg capsules (30-count package), with an ultimate completion date of September 24, 2025. This firm fixed price delivery order, awarded on September 3, 2025, represents a non-competitive set-aside contract and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical...
- SPE2DB24D2217Indefinite Delivery Contract
- SPE2DB24D2217-SPE2DB25FJWUJDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 21, 2025, for the supply of Ingrezza 40 mg capsules (30-count units) under a firm fixed-price arrangement with a ceiling value of $3,676.12. This is a non-set-aside competitive award with an ultimate completion date of May 12, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is one of the nation's largest pharmaceutical distributors and serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The IDC encompasses specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains, serving customers including the Defense Health Agency and U.S. Coast Guard. Ingrezza is a prescription antipsychotic medication used to treat involuntary movement disorders, and this order supports the federal government's pharmaceutical supply requirements for military medical facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 4/21/25 |